MITOXANTRONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N4O6
Molecular Weight	444.4809
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCNCCNC1=C2C(=O)C3=C(O)C=CC(O)=C3C(=O)C2=C(NCCNCCO)C=C1

InChI

InChIKey=KKZJGLLVHKMTCM-UHFFFAOYSA-N

InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2

HIDE SMILES / InChI

Molecular Formula	C22H28N4O6
Molecular Weight	444.4809
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf

Mitoxantrone (NOVANTRONE) is a synthetic antineoplastic anthracenedione. Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity. Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen pre sentation, as well as the secretion of interferon gamma, TNFα, and IL-2. NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). NOVANTRONE in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. NOVANTRONE in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Ubiquitin carboxyl-terminal hydrolase 11 2 Target ID: P51784 Gene ID: 8237.0 Gene Symbol: USP11 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23696131	Inhibitor 8504
DNA topoisomerase II alpha 37 Target ID: CHEMBL1806 Sources: https://www.drugbank.ca/drugs/DB01204 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11278845 \| https://www.ncbi.nlm.nih.gov/pubmed/9450803	Inhibitor 8504
DNA 282 Target ID: CHEMBL2311221 Sources: https://www.drugbank.ca/drugs/DB01204 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdff \| https://www.ncbi.nlm.nih.gov/pubmed/19284573 \| https://www.ncbi.nlm.nih.gov/pubmed/9701490	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Secondary progressive multiple sclerosis 5 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	Primary	Approved 8583	NOVANTRONE Approved Use Mitoxantrone injection USP (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone injection USP (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone injection USP (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone injection USP (concentrate) in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. Launch Date 1987
Acute non-lymphocytic leukemia 10 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	Primary	Approved 8583	NOVANTRONE Approved Use NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). NOVANTRONE is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. NOVANTRONE in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. NOVANTRONE in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. Launch Date 1987
Hormone-refractory prostate cancer 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	Primary	Approved 8583	NOVANTRONE Approved Use NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). NOVANTRONE is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. NOVANTRONE in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. NOVANTRONE in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. Launch Date 1987

C_max

Value	Dose	Co-administered	Analyte	Population
6.429 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8402672	90 mg/m² single, intravenous dose: 90 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		MITOXANTRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1.26 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1558794	12 mg/m² 1 times / 3 weeks multiple, intravenous dose: 12 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	MITOXANTRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
5.195 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8402672	90 mg/m² single, intravenous dose: 90 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	MITOXANTRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1922 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8410125	40 mg/m² single, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	MITOXANTRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
19.83 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1558794	12 mg/m² 1 times / 3 weeks multiple, intravenous dose: 12 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:		MITOXANTRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
37.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8410125	40 mg/m² single, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		MITOXANTRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
22% DRUG LABEL https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/fcb8ef8a-f770-4416-8fc5-fa01d98c8eee/spl-doc?hl=MITOXANTRONE			MITOXANTRONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
39 mg/m2 1 times / 4 weeks multiple, intravenous Highest studied dose Dose: 39 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 39 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/10445421/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/10445421/	DLT: Granulocytopenia... Other AEs: Thrombocytopenia, Nausea and vomiting... Dose limiting toxicities: Granulocytopenia (grade 4, 11 patient) Other AEs: Thrombocytopenia (grade 3, 11 patient) Nausea and vomiting (grade 1-2, 9 patients) Stomatitis (grade 1-3, 6 patients) Alopecia (grade 1-3, 5 patients) Diarrhea (grade 1-2, 3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/10445421/
12 mg/m2 1 times / 3 months multiple, intravenous Recommended Dose: 12 mg/m2, 1 times / 3 months Route: intravenous Route: multiple Dose: 12 mg/m2, 1 times / 3 months Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	Disc. AE: Urinary tract infection, Leukopenia... Other AEs: Nausea, Alopecia... AEs leading to discontinuation/dose reduction: Urinary tract infection (32%) Leukopenia (19%) Depression (1 patient) Left ventricular dysfunction (1 patient) Bone pain (1 patient) Emesis (1 patient) Renal failure (1 patient) Other AEs: Nausea (76%) Alopecia (61%) Menstrual disorder (61%) Amenorrhea (43%) Upper respiratory tract infection (53%) Stomatitis (19%) Arrhythmia (18%) Diarrhea (16%) Urine abnormal (11%) ECG abnormal (11%) Constipation (10%) Back pain (8%) Sinusitis (6%) Headache (6%) Gamma-GT increased (15%) SGOT increased (8%) Granulocytopenia (6%) Anemia (6%) SGPT increased (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 OATP1B3 961 OATP1B1 1079	OATP1B1 503 BCRP 697 MRP1 113 P-gp 2052	BCRP 101

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	no
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23680637/ \| https://pubmed.ncbi.nlm.nih.gov/22202118/ \| https://pubmed.ncbi.nlm.nih.gov/24036158/	weak [Ki 85 uM]
CYP2E1 1146	activator 342 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	weak
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25618019/	weak
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25618019/	yes [IC50 3.39 uM]
BCRP 985	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/10070941/	yes
MRP2 625	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/24036158/	yes
MRP4 345	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/24036158/	yes

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/20691148/	yes
MRP1 113	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16434618/	yes
OATP1B1 503	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26663398/	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9447822/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:50729	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50729
ChemicalBook	CB1246423	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1246423
eMolecules	742146	https://www.emolecules.com/cgi-bin/more?vid=742146
MolPort	MolPort-003-849-239	https://www.molport.com/shop/molecule-link/MolPort-003-849-239
ZINC	ZINC000003794794	http://zinc15.docking.org/substances/ZINC000003794794

PubMed

Title	Date	PubMed
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.	2001-08-15	11477562
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.	2001-08-01	11468181
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.	2001-08-01	11468148
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).	2001-08	11474261
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.	2001-08	11474254
The DNA helicase activity of yeast Sgs1p is essential for normal lifespan but not for resistance to topoisomerase inhibitors.	2001-08	11389927
Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.	2001-07-15	11454692
Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia.	2001-07-12	11446270
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.	2001-07-06	11437380
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.	2001-07-01	11395243
Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.	2001-07	11391720
Incremental net benefit in randomized clinical trials.	2001-06-15	11391688
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).	2001-06-06	11406094
Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.	2001-06-04	11378380
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.	2001-06	11475146
[Chemotherapy in gastroenterologic neuroendocrine tumors].	2001-06	11433719
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.	2001-06	11417484
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.	2001-06	11417475
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.	2001-06	11417473
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.	2001-06	11378344
Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis.	2001-05-31	11379324
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.	2001-05-15	11352963
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.	2001-05-15	11342422
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.	2001-05-01	11331330
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.	2001-05	11436111
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.	2001-05	11432629
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.	2001-05	11432625
Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study.	2001-05	11414146
Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study.	2001-05	11410417
In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.	2001-05	11410411
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.	2001-05	11368437
HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.	2001-04	11477443
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.	2001-04	11477440
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.	2001-04	11401094
High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.	2001-04	11378545
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.	2001-04	11360110
Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.	2001-04	11336612
Heterogeneity of proteinkinase C activity and PKC-zeta expression in clinical breast carcinomas.	2001-03	11467396
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.	2001-03	11350487
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.	2001-03	11350484
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.	2001-03	11342364
Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.	2001-03	11332989
Multiple sclerosis treatment 2001.	2001-02	11471759
Docetaxel in prostate cancer.	2001-02	11340899
Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.	2001-01	11426554
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.	2001-01	11426553
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.	2001-01	11426487
A systematic overview of chemotherapy effects in acute myeloid leukaemia.	2001	11441935
Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.	2001	11414199
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.	2001	11338878

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of NOVANTRONE (Mitoxantrone) is 12 mg/m2 given as a short (approximately 5 to 15 minutes) intravenous infusion every 3 months.

Route of Administration: Intravenous

In Vitro Use Guide

Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 ug/ml) induced a decrease in cell viability as determined by MTT assay.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:46:54 GMT 2025` Edited by `admin` on `Mon Mar 31 17:46:54 GMT 2025`
Record UNII	BZ114NVM5P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MISOSTOL

Preferred Name

English

MITOXANTRONE

Official Name

English

mitoxantrone [INN]

Common Name

English

NSC-279836

Code

English

MITOXANTRONE [IARC]

Common Name

English

Mitoxantrone [WHO-DD]

Common Name

English

Mitozantrone

Common Name

English

MITOXANTRONE [VANDF]

Common Name

English

MITOXANTRONE [MI]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

128499